Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Net Assets
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has net assets worth $819.93 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.60 Billion) and total liabilities ($2.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Amneal Pharmaceuticals, Inc. Class A Com to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $819.93 Million |
| % of Total Assets | 22.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -112.91% |
| 10-Year Change | N/A |
| Growth Volatility | 111.26 |
Amneal Pharmaceuticals, Inc. Class A Common Stock - Net Assets Trend (2015–2024)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Amneal Pharmaceuticals, Inc. Class A Com for the complete picture of this company's asset base.
Annual Net Assets for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below shows the annual net assets of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024. For live valuation and market cap data, see AMRX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-44.54 Million | -322.57% |
| 2023-12-31 | $20.01 Million | -90.42% |
| 2022-12-31 | $208.93 Million | -43.07% |
| 2021-12-31 | $366.97 Million | +6.39% |
| 2020-12-31 | $344.93 Million | -0.54% |
| 2019-12-31 | $346.79 Million | -61.31% |
| 2018-12-31 | $896.36 Million | +338.66% |
| 2017-12-31 | $-375.58 Million | -113.47% |
| 2016-12-31 | $-175.94 Million | +5.85% |
| 2015-12-31 | $-186.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amneal Pharmaceuticals, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42508800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.10 Million | % |
| Other Comprehensive Income | $-65.51 Million | % |
| Other Components | $560.21 Million | % |
| Total Equity | $-109.27 Million | 100.00% |
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hainan Mining Co Ltd
SHG:601969
|
$3.58 Billion |
|
GZ Port
SHG:601228
|
$3.58 Billion |
|
Maximus Inc
NYSE:MMS
|
$3.58 Billion |
|
Olav Thon Eien
OL:OLT
|
$3.58 Billion |
|
Glanbia PLC
IR:GL9
|
$3.57 Billion |
|
ELF Beauty Inc
NYSE:ELF
|
$3.57 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
$3.57 Billion |
|
Cactus Inc
NYSE:WHD
|
$3.57 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amneal Pharmaceuticals, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,781,000 to -109,267,000, a change of -129,048,000 (-652.4%).
- Net loss of 116,886,000 reduced equity.
- Share repurchases of 7,952,000 reduced equity.
- Other comprehensive income decreased equity by 33,161,000.
- Other factors increased equity by 28,951,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-116.89 Million | -106.97% |
| Share Repurchases | $7.95 Million | -7.28% |
| Other Comprehensive Income | $-33.16 Million | -30.35% |
| Other Changes | $28.95 Million | +26.5% |
| Total Change | $- | -652.38% |
Book Value vs Market Value Analysis
This analysis compares Amneal Pharmaceuticals, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-1.03 | $12.18 | x |
| 2016-12-31 | $-0.98 | $12.18 | x |
| 2017-12-31 | $-3.36 | $12.18 | x |
| 2018-12-31 | $7.04 | $12.18 | x |
| 2019-12-31 | $2.63 | $12.18 | x |
| 2020-12-31 | $2.32 | $12.18 | x |
| 2021-12-31 | $2.37 | $12.18 | x |
| 2022-12-31 | $1.98 | $12.18 | x |
| 2023-12-31 | $0.11 | $12.18 | x |
| 2024-12-31 | $-0.35 | $12.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amneal Pharmaceuticals, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.18%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-63.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 19.56% | 0.85x | 0.00x | $188.97 Million |
| 2016 | 0.00% | 20.37% | 0.84x | 0.00x | $225.91 Million |
| 2017 | 0.00% | 16.22% | 0.77x | 0.00x | $206.22 Million |
| 2018 | -18.93% | -10.21% | 0.38x | 4.86x | $-259.36 Million |
| 2019 | -174.05% | -37.11% | 0.44x | 10.57x | $-638.25 Million |
| 2020 | 26.40% | 4.57% | 0.50x | 11.61x | $56.57 Million |
| 2021 | 2.95% | 0.51% | 0.53x | 10.93x | $-25.41 Million |
| 2022 | -43.56% | -5.88% | 0.58x | 12.73x | $-159.83 Million |
| 2023 | -424.61% | -3.51% | 0.69x | 175.55x | $-85.97 Million |
| 2024 | 0.00% | -4.18% | 0.80x | 0.00x | $-105.96 Million |
Industry Comparison
This section compares Amneal Pharmaceuticals, Inc. Class A Common Stock's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $410,818,833
- Average return on equity (ROE) among peers: -68.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $819.93 Million | 0.00% | 3.39x | $3.57 Billion |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $164.76 Million | -183.14% | 0.18x | $1.77 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.80 Billion |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more